Added benefits of drospirenone for compliance

@article{Foidart2005AddedBO,
  title={Added benefits of drospirenone for compliance},
  author={J. Foidart},
  journal={Climacteric},
  year={2005},
  volume={8},
  pages={28 - 34}
}
Drospirenone is a novel progestogen that possesses antimineralocorticoid activity. This activity is seen clinically in its effects on physiological parameters, body weight, general well-being and fluid-related symptoms. Clinical studies with an oral contraceptive containing 30 μg ethinylestradiol and 3 mg drospirenone (Yasmin®, Schering AG, Berlin, Germany) and a new continuous combined oral hormone replacement therapy (HRT) containing 1 mg 17β-estradiol and 2 mg drospirenone (Angeliq… Expand
Drospirenone: a novel progestin
Drospirenone and estradiol: a new option for the postmenopausal woman
  • D. Archer
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2007
Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms
  • O. Ylikorkala
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2005
Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
  • J. Foidart
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone
  • J. Huber, J. Foidart, +5 authors R. Heithecker
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms
  • D. Apter, A. Borsos, +5 authors S. Kelly
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2003
Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
  • E. Freeman
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2002
...
1
2
3
...